PULMATRIX, INC. Restricted Cash
PULMATRIX, INC. (PULM) had Restricted Cash of $700.00 thousand as of 2026-06-30, per its S-4/A filed 2026-09-17.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCash · last filed 2026-09-17
- 2026-06-30: Restricted Cash $700.00K.
- 2026-03-31: Restricted Cash $700.00K.
| Period end | Restricted Cash |
|---|---|
| 2026-06-30 | $700.00K S-4/A · filed 2026-09-17 |
| 2026-03-31 | $700.00K S-4/A · filed 2026-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |